Search
Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
World Patient Safety Day 2021
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Hovione is recognized as a Top Employer 2023
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions
Hovione commitment to setting SBTs in line with the Paris Agreement
Hovione meets increased demand during Covid
Irish Examiner, 21 june 2021
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Hovione Unveils New Continuous Tableting Line at Lisbon R&D Centre
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.